- Home
- PASG
PASG
Passage Bio Inc.
as 12-18-2024 12:41pm EST
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 42.2M | IPO Year: | 2020 |
| Target Price: | $8.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.45 - $1.79 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Passage Bio Inc. (PASG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Dec 9 '24 | Sell | $0.81 | 62,276 | $51,988.04 | 7,643,285 | |
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Dec 4 '24 | Sell | $0.80 | 97,103 | $77,338.46 | 7,643,285 | |
| Lynx1 Capital Management LP | PASG | 10% Owner | Nov 25 '24 | Buy | $0.65 | 456,353 | $284,519.51 | 8,854,008 | |
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Sep 19 '24 | Sell | $0.71 | 39,300 | $27,903.00 | 7,643,285 |
Latest Passage Bio Inc. News
PASG Breaking Stock News: Dive into PASG Ticker-Specific Updates for Smart Investing
TipRanks
18 days ago
Passage Bio assumed with an Outperform at Wedbush
MT Newswires
19 days ago
Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating
MT Newswires
19 days ago
Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating
TipRanks
a month ago
Passage Bio Achieves Milestones in Gene Therapy Trials
GlobeNewswire
a month ago
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
a month ago
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
GlobeNewswire
2 months ago
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
GuruFocus.com
3 months ago
Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc
Compare PASG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PASG Passage Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.